Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Farapulse Inc.
In an interview with Medtech Insight, Angelo De Rosa, the general manager of Boston Scientific’s cardiac rhythm management and electrophysiology businesses in Europe, Middle East and Africa (EMEA), discussed some of his company’s recent achievements and the opportunities it is addressing in 2022.
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the third day of the meeting.
Boston Scientific will exercise its option to buy the remaining 73% of Farapulse, the first company to market a pulsed field cardiac ablation system.
Two pivotal US trials of pulsed field ablation systems began in early March. Farapulse is sponsoring the ADVENT randomized trial of the Farapulse PFA system and Medtronic launched the international PULSED AF trial of its PulseSelect PFA system.
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- Iowa Approach Inc.